
Opinion|Videos|May 7, 2024
Efficacy and Safety of Aflibercept 8 mg in PULSAR Trial in Neovascular AMD
Author(s)Marion Munk, MD, PhD
Dr. Marion Munk reviews the Phase 3 clinical trial of high-dose aflibercept (8 mg) in neovascular AMD, emphasizing how this new therapy could alleviate the treatment burden for patients while providing superior outcomes.
Advertisement
Episodes in this series
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
The Atrophy Advisor: An online tool to inform GA treatment decisions
2
FLORetina 2025: EU-ROP Registry bridges borders for real-world insight
3
FLORetina 2025: Updates on tinlarebant in adolescent Stargardt disease
4
Enhancing Durability and Fluid Control with Aflibercept 8 mg in Retinal Vascular Diseases
5









































